Inter-lobar Fissure Completion in Patients With Failed Bronchoscopic Lung Volume Reduction
NCT ID: NCT05257681
Last Updated: 2025-04-06
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
20 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-05-24
Study Completion Date
2026-05-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this protocol is to perform a pilot prospective controlled clinical trial to evaluate the potential role of lung fissure completion with pleural adhesiolysis strategy (experimental intervention) in severe emphysema/COPD patients with failed bronchoscopic lung volume reduction (BLVR) via the use of endobronchial valves (EBVs) therapy. In select patients, the lung fissure completion with adhesiolysis strategy will be performed by video-assisted thoracoscopic surgery (VATS) guided stapling along the lung fissures to reduce collateral ventilation with adhesions removal and determine whether this experimental strategy will improve outcomes after failed BLVR in patients with severe emphysema/COPD.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combined Zephyr Valve System With Inter-lobar Fissure Completion for Lung Volume Reduction in Emphysema
NCT04801108
Emphysema or COPD
RECRUITING
NA
Functional Lung Imaging in Patients With Respiratory Compromise Undergoing Endobronchial Valve Placement
NCT05204875
Emphysema
UNKNOWN
Use of Endobronchial Valves in Non-Upper Lobe Heterogeneous Emphysema
NCT00825578
Heterogeneous Emphysema
COMPLETED
PHASE3
Surgical Compared to Bronchoscopic Lung Volume Reduction in Patients With Severe Emphysema
NCT04537182
Emphysema
RECRUITING
NA
Bronchioscopic Lung Volume Reduction (BLVR)
NCT02415478
Chronic Obstructive Pulmonary Disease (COPD)
UNKNOWN
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators will approach all patients with failed EBV therapy. Patients with less than 350 ml of volume reduction in the target lobe and persistent dyspnea \[score greater or equal to 2 on the Modified Medical Research Council Dyspnea Scale (mMRC)\] after EBV placement will be considered to have failed EBV therapy due to adhesions or collateral ventilation being present. Only patients with failed EBV therapy will be approached to participate in our study. Once the patient agrees to participate and sign the consent, all the screening information collected as part of the standard of care will be extracted retrospectively from the medical records including appointment details, 6MWD, and PFTs results. In addition, during the same visit, health-related quality of life will be measured using the Saint George Respiratory Questionnaire (SGRQ) and COPD Assessment Test (CAT), and dyspnea will be assessed with the self-reported mMRC.
VATS Inter-Lobar Fissure Completion and Pleural Adhesiolysis The clinician providing general anesthesia will be familiar with thoracic anesthesia and complications in patients with severe COPD undergoing thoracic surgery and endoscopic valve implantation. Total IV anesthesia will be used during all bronchoscopic procedures. Routine antimicrobial prophylaxis will be administered at induction. The antimicrobial choice will be based on the subject's allergies and/or history of resistant organisms.
The experimental procedure will be performed via VATS under inhaled anesthetic agents by an experienced thoracic surgeon from BIDMC. The clinician providing general anesthesia will be familiar with thoracic anesthesia and complications in patients with severe COPD undergoing thoracic surgery and endoscopic valve implantation. A double-lumen endotracheal tube will be inserted allowing one-lung ventilation and the maximal collapse of the operative lung. The subject will be placed in lateral decubitus with the operative side up. Disinfection of the surgical site will be performed with the application of an antiseptic solution and the subject will be draped in the usual sterile fashion. The thoracic surgeon will perform multiple rib blocks and inject the skin incisions with bupivacaine. Through small incisions, the surgeon will create a camera port through the intercostal space and then the anterior and posterior inferior ports. Electrocautery will be used for adhesion release of the ipsilateral lung of the target lobe. Dissection and exposure of the anterior aspect of the hilum will then be performed using electrocautery. Following the exposure, stapling will be performed on the incomplete fissure adjacent to the target lobe, using the Endo GIATM (CovidienTM, Mansfield, MA) FDA-approved surgical stapler. The lung tissue will be dissected until the pulmonary artery is seen, in a similar fashion to the method used in lobectomies and segmentectomies. Multiple surgical stapler activations will be used to complete the target fissure along the fissure line.
An attempt at conversion to a complete fissure will be made, though depending on the anatomy, it may be possible that residual incomplete fissure of up to 5% may be tolerated. Hemostasis will be evaluated. Sterile water will then be used to fill the surgical area, followed by lung inflation and inspection to verify for air leaks at the level of the stapling. If an air leak is detected, suturing, re-stapling, or applying pleural sealants will be used to seal it. The patient will be monitored closely for air leaks in the postoperative setting in case there is the persistence of the air leak despite the measures taken and valve presence, a second intervention will be considered based on the thoracic surgeon's judgment. Once the fissure is surgically completed, a chest tube will be placed and connected to a chest drainage system.
In the setting that the thoracic surgeon will not be able to complete the fissure up to 95% due to anatomic restraints, the procedure will then be ended without valve implantation, as the presence of residual collateral ventilation is expected. All patients will receive standard of care post-operative management, and subjects will continue to be followed for any procedure-related adverse events until the event has subsided or, in case of permanent impairment, until the event stabilizes, and the overall clinical outcome has been ascertained. At that time, the subject will be withdrawn from the study and will be considered as an "Enrollment Failure" and recorded as such for statistical analysis.
Bronchoscopic Evaluation The double-lumen endotracheal tube will be removed, and a single-lumen tube (8.0 to 8.5 mm) inserted. The lung will be completely re-inflated before this evaluation to return them to normal anatomy.
Flexible bronchoscopy will be done by the interventional pulmonologist. The bronchoscope will be passed via the endotracheal tube and the major airways will be examined. The placement of the EBVs will be assessed. In case one of the valves is not adequately placed, the interventional pulmonologist will adjust it. If any valve needs to be replaced, the replacement will be performed at this point. A bronchial wash will be performed with samples sent for culture. If there are unexpected findings, such as a lesion suspicious for carcinoma or secretions suggesting infection, then appropriate clinical samples will be obtained, and the subject will be re-evaluated, the study team will then determine if the subject will be withdrawn from the study and will be considered as an "Enrollment Failure" and recorded as such for statistical analysis.
Postoperative Persistent Air-Leak Management In the setting of a persisting air-leak \> 5 days after the procedure, the investigator will proceed to the removal of the most proximal valve from the treated lobe (if the left upper lobe is the treatment lobe, the removal will be from a lingular segment). If there is a resolution of the air leak within 48 hours, replacement of the valve will be considered and scheduled in 6 weeks. During the valve replacement procedure, if previously placed valves are observed to be sub-optimally placed, the investigator may remove and replace any sub-optimally placed valves.
If the air leak does not resolve within 48 hours after the first valve removal, all remaining valves will be removed. In the setting of a persistent air-leak despite previous interventions, further management will be based on the investigator's judgment and per standard of care (chemical pleurodesis or conservative management). Chest tube maintenance \> 7 days in presence of a persistent air leak will also be considered as a thoracic serious adverse event and recorded in the AE CRF as part of the study's safety evaluation.
The management algorithm for persistent air-leaks was adapted from the expert consensus by Valipour et al. Clinical management of persistent air-leaks may vary depending on clinical circumstances, so exceptions to these guidelines will not be considered protocol deviations.
Pneumothorax Management Pneumothorax after valve placement can be an effect of the desired treatment response that is associated with complete lobe treatment and atelectasis. The management of pneumothorax is an integral part of the treatment. The origin is thought to be from the rupture of stretched diseased tissue that is adjacent to the volume reduced lobe. Management for pneumothorax associated with EBVs will be conducted according to expert consensus and our internal algorithm, which represents standard-of-care for pneumothorax management.
Follow-up Period After VATS fissure completion and adhesiolysis, patients will be placed on a standardized follow-up protocol used for individuals that underwent video-assisted thoracic surgery. Data from follow-up appointments at 14 days and 3 months will be collected from the medical records retrospectively including appointment details, complications, CT-scan results, 6MWD, and PFTs results. Target lung volume reduction (TLVR) will be assessed at 3 months using the CT scans performed on patients as part of their standard of care. The only procedures that will be considered research after the initial surgical intervention would be the measurement of health-related quality of life with the SGRQ and CAT, and dyspnea assessment with the self-reported mMRC at 3 months.
VATS Inter-Lobar Fissure Completion and Pleural Adhesiolysis The clinician providing general anesthesia will be familiar with thoracic anesthesia and complications in patients with severe COPD undergoing thoracic surgery and endoscopic valve implantation. Total IV anesthesia will be used during all bronchoscopic procedures. Routine antimicrobial prophylaxis will be administered at induction. The antimicrobial choice will be based on the subject's allergies and/or history of resistant organisms.
The experimental procedure will be performed via VATS under inhaled anesthetic agents by an experienced thoracic surgeon from BIDMC. The clinician providing general anesthesia will be familiar with thoracic anesthesia and complications in patients with severe COPD undergoing thoracic surgery and endoscopic valve implantation. A double-lumen endotracheal tube will be inserted allowing one-lung ventilation and the maximal collapse of the operative lung. The subject will be placed in lateral decubitus with the operative side up. Disinfection of the surgical site will be performed with the application of an antiseptic solution and the subject will be draped in the usual sterile fashion. The thoracic surgeon will perform multiple rib blocks and inject the skin incisions with bupivacaine. Through small incisions, the surgeon will create a camera port through the intercostal space and then the anterior and posterior inferior ports. Electrocautery will be used for adhesion release of the ipsilateral lung of the target lobe. Dissection and exposure of the anterior aspect of the hilum will then be performed using electrocautery. Following the exposure, stapling will be performed on the incomplete fissure adjacent to the target lobe, using the Endo GIATM (CovidienTM, Mansfield, MA) FDA-approved surgical stapler. The lung tissue will be dissected until the pulmonary artery is seen, in a similar fashion to the method used in lobectomies and segmentectomies. Multiple surgical stapler activations will be used to complete the target fissure along the fissure line.
An attempt at conversion to a complete fissure will be made, though depending on the anatomy, it may be possible that residual incomplete fissure of up to 5% may be tolerated. Hemostasis will be evaluated. Sterile water will then be used to fill the surgical area, followed by lung inflation and inspection to verify for air leaks at the level of the stapling. If an air leak is detected, suturing, re-stapling, or applying pleural sealants will be used to seal it. The patient will be monitored closely for air leaks in the postoperative setting in case there is the persistence of the air leak despite the measures taken and valve presence, a second intervention will be considered based on the thoracic surgeon's judgment. Once the fissure is surgically completed, a chest tube will be placed and connected to a chest drainage system.
In the setting that the thoracic surgeon will not be able to complete the fissure up to 95% due to anatomic restraints, the procedure will then be ended without valve implantation, as the presence of residual collateral ventilation is expected. All patients will receive standard of care post-operative management, and subjects will continue to be followed for any procedure-related adverse events until the event has subsided or, in case of permanent impairment, until the event stabilizes, and the overall clinical outcome has been ascertained. At that time, the subject will be withdrawn from the study and will be considered as an "Enrollment Failure" and recorded as such for statistical analysis.
Bronchoscopic Evaluation The double-lumen endotracheal tube will be removed, and a single-lumen tube (8.0 to 8.5 mm) inserted. The lung will be completely re-inflated before this evaluation to return them to normal anatomy.
Flexible bronchoscopy will be done by the interventional pulmonologist. The bronchoscope will be passed via the endotracheal tube and the major airways will be examined. The placement of the EBVs will be assessed. In case one of the valves is not adequately placed, the interventional pulmonologist will adjust it. If any valve needs to be replaced, the replacement will be performed at this point. A bronchial wash will be performed with samples sent for culture. If there are unexpected findings, such as a lesion suspicious for carcinoma or secretions suggesting infection, then appropriate clinical samples will be obtained, and the subject will be re-evaluated, the study team will then determine if the subject will be withdrawn from the study and will be considered as an "Enrollment Failure" and recorded as such for statistical analysis.
Postoperative Persistent Air-Leak Management In the setting of a persisting air-leak \> 5 days after the procedure, the investigator will proceed to the removal of the most proximal valve from the treated lobe (if the left upper lobe is the treatment lobe, the removal will be from a lingular segment). If there is a resolution of the air leak within 48 hours, replacement of the valve will be considered and scheduled in 6 weeks. During the valve replacement procedure, if previously placed valves are observed to be sub-optimally placed, the investigator may remove and replace any sub-optimally placed valves.
If the air leak does not resolve within 48 hours after the first valve removal, all remaining valves will be removed. In the setting of a persistent air-leak despite previous interventions, further management will be based on the investigator's judgment and per standard of care (chemical pleurodesis or conservative management). Chest tube maintenance \> 7 days in presence of a persistent air leak will also be considered as a thoracic serious adverse event and recorded in the AE CRF as part of the study's safety evaluation.
The management algorithm for persistent air-leaks was adapted from the expert consensus by Valipour et al. Clinical management of persistent air-leaks may vary depending on clinical circumstances, so exceptions to these guidelines will not be considered protocol deviations.
Pneumothorax Management Pneumothorax after valve placement can be an effect of the desired treatment response that is associated with complete lobe treatment and atelectasis. The management of pneumothorax is an integral part of the treatment. The origin is thought to be from the rupture of stretched diseased tissue that is adjacent to the volume reduced lobe. Management for pneumothorax associated with EBVs will be conducted according to expert consensus and our internal algorithm, which represents standard-of-care for pneumothorax management.
Follow-up Period After VATS fissure completion and adhesiolysis, patients will be placed on a standardized follow-up protocol used for individuals that underwent video-assisted thoracic surgery. Data from follow-up appointments at 14 days and 3 months will be collected from the medical records retrospectively including appointment details, complications, CT-scan results, 6MWD, and PFTs results. Target lung volume reduction (TLVR) will be assessed at 3 months using the CT scans performed on patients as part of their standard of care. The only procedures that will be considered research after the initial surgical intervention would be the measurement of health-related quality of life with the SGRQ and CAT, and dyspnea assessment with the self-reported mMRC at 3 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Emphysema or COPD
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
This study is expected to enroll a total of 20 subjects with a follow-up period of 3 months. All interventions and follow-up will be performed at the BIDMC. In current medical practice, emphysema patients that fail to achieve target lung volume reduction after endobronchial valves placement, are continued on current medical management for their COPD, with consideration for lung transplantation should they be eligible depending on clinical circumstances and degree of lung function impairment. The investigators plan to offer this patient population the possibility to undergo a VATS fissure completion and adhesiolysis.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fissure completion and adhesiolysis arm
Patients will undergo a VATS or robotic interlobar lung fissure completion with pleural adhesiolysis. After a 3 month follow-up period, patients will fill additional quality of life questionnaires including the St.George Respiratory Questionnaire, COPD Assessment tool, and the modified medical research council dyspnea scale. Pulmonary function testing and a high-resolution CT scan will be performed at the end of the 3-month postoperative follow-up.
Group Type
EXPERIMENTAL
Interlobar fissure completion and pleural adhesiolysis
Intervention Type
PROCEDURE
A video-assisted thoracic surgery or robotic approach will be used to perform pleural adhesiolysis and the lobar fissure adjacent to the previously targeted lobe during bronchoscopic lung volume reduction will be completed using a surgical stapler.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Interlobar fissure completion and pleural adhesiolysis
A video-assisted thoracic surgery or robotic approach will be used to perform pleural adhesiolysis and the lobar fissure adjacent to the previously targeted lobe during bronchoscopic lung volume reduction will be completed using a surgical stapler.
Intervention Type
PROCEDURE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 40 to 75 years.
* Stable with less than 10mg prednisone (or equivalent) daily.
* Nonsmoking for 4 months prior to screening and willing to not smoke during the study duration.
* Current pneumococcus vaccination.
* Current influenza vaccination.
* Target lung volume reduction \<350ml after bronchoscopic lung volume reduction (BLVR).
* Persistent dyspnea defined as an mMRC score greater or equal to 2 after bronchoscopic lung volume reduction (BLVR).
* Endobronchial valves (EBV) are still in place.
* Willing and able to complete protocol required study follow-up assessments and procedures.
* Stable with less than 10mg prednisone (or equivalent) daily.
* Nonsmoking for 4 months prior to screening and willing to not smoke during the study duration.
* Current pneumococcus vaccination.
* Current influenza vaccination.
* Target lung volume reduction \<350ml after bronchoscopic lung volume reduction (BLVR).
* Persistent dyspnea defined as an mMRC score greater or equal to 2 after bronchoscopic lung volume reduction (BLVR).
* Endobronchial valves (EBV) are still in place.
* Willing and able to complete protocol required study follow-up assessments and procedures.
Exclusion Criteria
* Clinically significant (greater than 4 tablespoons per day) mucus production.
* Myocardial infarction within 6 months of screening.
* Decompensated heart failure.
* Three or more pneumonia episodes in last year.
* Three or more COPD exacerbation episodes in the last year.
* Prior lung transplant, LVRS, bullectomy, or lobectomy.
* Clinically significant bronchiectasis.
* Unable to safely discontinue anticoagulants or platelet activity inhibitors for 7 days.
* Uncontrolled pulmonary hypertension (systolic pulmonary arterial pressure \>45mmHg) or evidence or history of CorPulmonale as determined by a recent echocardiogram (completed within the last 3 months prior to screening visit).
* Left ventricular ejection fraction (LVEF) less than 40% as determined by a recent echocardiogram (completed within the last 3 months prior to screening visit).
* Resting bradycardia (\<50 bpm), Complex ventricular arrhythmia, sustained SVT.
* PaCO2 greater than 50mmHg on room air at screening.
* PaO2 less than 45mmHg on room air at screening.
* Myocardial infarction within 6 months of screening.
* Decompensated heart failure.
* Three or more pneumonia episodes in last year.
* Three or more COPD exacerbation episodes in the last year.
* Prior lung transplant, LVRS, bullectomy, or lobectomy.
* Clinically significant bronchiectasis.
* Unable to safely discontinue anticoagulants or platelet activity inhibitors for 7 days.
* Uncontrolled pulmonary hypertension (systolic pulmonary arterial pressure \>45mmHg) or evidence or history of CorPulmonale as determined by a recent echocardiogram (completed within the last 3 months prior to screening visit).
* Left ventricular ejection fraction (LVEF) less than 40% as determined by a recent echocardiogram (completed within the last 3 months prior to screening visit).
* Resting bradycardia (\<50 bpm), Complex ventricular arrhythmia, sustained SVT.
* PaCO2 greater than 50mmHg on room air at screening.
* PaO2 less than 45mmHg on room air at screening.
Minimum Eligible Age
40 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beth Israel Deaconess Medical Center
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adnan Majid, MD
Chief Interventional Pulmonology
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Wheaton AG, Cunningham TJ, Ford ES, Croft JB; Centers for Disease Control and Prevention (CDC). Employment and activity limitations among adults with chronic obstructive pulmonary disease--United States, 2013. MMWR Morb Mortal Wkly Rep. 2015 Mar 27;64(11):289-95.
Reference Type
BACKGROUND
Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global Strategy for the Diagnosis, Management, and Prevention of COPD 2022.
Reference Type
BACKGROUND
Hartman JE, Vanfleteren LEGW, van Rikxoort EM, Klooster K, Slebos DJ. Endobronchial valves for severe emphysema. Eur Respir Rev. 2019 Apr 17;28(152):180121. doi: 10.1183/16000617.0121-2018. Print 2019 Jun 30.
Reference Type
BACKGROUND
Majid A, Kheir F, Alape D, Chee A, Parikh M, DeVore L, Agnew A, Gangadharan S. Combined Thoracoscopic Surgical Stapling and Endobronchial Valve Placement For Lung Volume Reduction With Incomplete Lobar Fissures: An Experimental Pilot Animal Study. J Bronchology Interv Pulmonol. 2020 Apr;27(2):128-134. doi: 10.1097/LBR.0000000000000617.
Reference Type
BACKGROUND
Celli BR, Wedzicha JA. Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. N Engl J Med. 2019 Sep 26;381(13):1257-1266. doi: 10.1056/NEJMra1900500. No abstract available.
Reference Type
BACKGROUND
Kochanek KD, Murphy S, Xu J, Arias E. Mortality in the United States, 2016. NCHS Data Brief. 2017 Dec;(293):1-8.
Reference Type
BACKGROUND
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov;3(11):e442. doi: 10.1371/journal.pmed.0030442.
Reference Type
BACKGROUND
GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017 Sep;5(9):691-706. doi: 10.1016/S2213-2600(17)30293-X. Epub 2017 Aug 16.
Reference Type
BACKGROUND
Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest. 2000 Feb;117(2 Suppl):5S-9S. doi: 10.1378/chest.117.2_suppl.5s.
Reference Type
BACKGROUND
Rennard SI. COPD: overview of definitions, epidemiology, and factors influencing its development. Chest. 1998 Apr;113(4 Suppl):235S-241S. doi: 10.1378/chest.113.4_supplement.235s.
Reference Type
BACKGROUND
Maltais F, Decramer M, Casaburi R, Barreiro E, Burelle Y, Debigare R, Dekhuijzen PN, Franssen F, Gayan-Ramirez G, Gea J, Gosker HR, Gosselink R, Hayot M, Hussain SN, Janssens W, Polkey MI, Roca J, Saey D, Schols AM, Spruit MA, Steiner M, Taivassalo T, Troosters T, Vogiatzis I, Wagner PD; ATS/ERS Ad Hoc Committee on Limb Muscle Dysfunction in COPD. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014 May 1;189(9):e15-62. doi: 10.1164/rccm.201402-0373ST.
Reference Type
BACKGROUND
Maltais F. Exercise and COPD: therapeutic responses, disease-related outcomes, and activity-promotion strategies. Phys Sportsmed. 2013 Feb;41(1):66-80. doi: 10.3810/psm.2013.02.2001.
Reference Type
BACKGROUND
Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood DE; National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003 May 22;348(21):2059-73. doi: 10.1056/NEJMoa030287. Epub 2003 May 20.
Reference Type
BACKGROUND
Fessler HE, Permutt S. Lung volume reduction surgery and airflow limitation. Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):715-22. doi: 10.1164/ajrccm.157.3.9608004.
Reference Type
BACKGROUND
Naunheim KS, Wood DE, Krasna MJ, DeCamp MM Jr, Ginsburg ME, McKenna RJ Jr, Criner GJ, Hoffman EA, Sternberg AL, Deschamps C; National Emphysema Treatment Trial Research Group. Predictors of operative mortality and cardiopulmonary morbidity in the National Emphysema Treatment Trial. J Thorac Cardiovasc Surg. 2006 Jan;131(1):43-53. doi: 10.1016/j.jtcvs.2005.09.006. Epub 2005 Dec 5.
Reference Type
BACKGROUND
DeCamp MM Jr, McKenna RJ Jr, Deschamps CC, Krasna MJ. Lung volume reduction surgery: technique, operative mortality, and morbidity. Proc Am Thorac Soc. 2008 May 1;5(4):442-6. doi: 10.1513/pats.200803-023ET.
Reference Type
BACKGROUND
DeCamp MM, Blackstone EH, Naunheim KS, Krasna MJ, Wood DE, Meli YM, McKenna RJ Jr; NETT Research Group. Patient and surgical factors influencing air leak after lung volume reduction surgery: lessons learned from the National Emphysema Treatment Trial. Ann Thorac Surg. 2006 Jul;82(1):197-206; discussion 206-7. doi: 10.1016/j.athoracsur.2006.02.050.
Reference Type
BACKGROUND
Labarca G, Uribe JP, Pacheco C, Folch E, Kheir F, Majid A, Jantz MA, Mehta HJ, Patel N, Herth FJF, Fernandez-Bussy S. Bronchoscopic Lung Volume Reduction with Endobronchial Zephyr Valves for Severe Emphysema: A Systematic Review and Meta-Analysis. Respiration. 2019;98(3):268-278. doi: 10.1159/000499508. Epub 2019 May 22.
Reference Type
BACKGROUND
Sciurba FC, Ernst A, Herth FJ, Strange C, Criner GJ, Marquette CH, Kovitz KL, Chiacchierini RP, Goldin J, McLennan G; VENT Study Research Group. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med. 2010 Sep 23;363(13):1233-44. doi: 10.1056/NEJMoa0900928.
Reference Type
BACKGROUND
Eberhardt R, Gompelmann D, Schuhmann M, Reinhardt H, Ernst A, Heussel CP, Herth FJF. Complete unilateral vs partial bilateral endoscopic lung volume reduction in patients with bilateral lung emphysema. Chest. 2012 Oct;142(4):900-908. doi: 10.1378/chest.11-2886.
Reference Type
BACKGROUND
Shah PL, Herth FJ. Current status of bronchoscopic lung volume reduction with endobronchial valves. Thorax. 2014 Mar;69(3):280-6. doi: 10.1136/thoraxjnl-2013-203743. Epub 2013 Sep 5.
Reference Type
BACKGROUND
Cetti EJ, Moore AJ, Geddes DM. Collateral ventilation. Thorax. 2006 May;61(5):371-3. doi: 10.1136/thx.2006.060509.
Reference Type
BACKGROUND
Koster TD, Slebos DJ. The fissure: interlobar collateral ventilation and implications for endoscopic therapy in emphysema. Int J Chron Obstruct Pulmon Dis. 2016 Apr 13;11:765-73. doi: 10.2147/COPD.S103807. eCollection 2016.
Reference Type
BACKGROUND
Koster TD, van Rikxoort EM, Huebner RH, Doellinger F, Klooster K, Charbonnier JP, Radhakrishnan S, Herth FJ, Slebos DJ. Predicting Lung Volume Reduction after Endobronchial Valve Therapy Is Maximized Using a Combination of Diagnostic Tools. Respiration. 2016;92(3):150-7. doi: 10.1159/000448849. Epub 2016 Aug 31.
Reference Type
BACKGROUND
Gompelmann D, Eberhardt R, Slebos DJ, Brown MS, Abtin F, Kim HJ, Holmes-Higgin D, Radhakrishnan S, Herth FJ, Goldin J. Diagnostic performance comparison of the Chartis System and high-resolution computerized tomography fissure analysis for planning endoscopic lung volume reduction. Respirology. 2014 May;19(4):524-30. doi: 10.1111/resp.12253. Epub 2014 Feb 25.
Reference Type
BACKGROUND
Herth FJ, Eberhardt R, Gompelmann D, Ficker JH, Wagner M, Ek L, Schmidt B, Slebos DJ. Radiological and clinical outcomes of using Chartis to plan endobronchial valve treatment. Eur Respir J. 2013 Feb;41(2):302-8. doi: 10.1183/09031936.00015312. Epub 2012 May 3.
Reference Type
BACKGROUND
Herth FJF, Slebos DJ, Criner GJ, Valipour A, Sciurba F, Shah PL. Endoscopic Lung Volume Reduction: An Expert Panel Recommendation - Update 2019. Respiration. 2019;97(6):548-557. doi: 10.1159/000496122. Epub 2019 Mar 5.
Reference Type
BACKGROUND
Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, Marciniuk DD, Denberg T, Schunemann H, Wedzicha W, MacDonald R, Shekelle P; American College of Physicians; American College of Chest Physicians; American Thoracic Society; European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011 Aug 2;155(3):179-91. doi: 10.7326/0003-4819-155-3-201108020-00008.
Reference Type
BACKGROUND
Slebos DJ, Shah PL, Herth FJ, Valipour A. Endobronchial Valves for Endoscopic Lung Volume Reduction: Best Practice Recommendations from Expert Panel on Endoscopic Lung Volume Reduction. Respiration. 2017;93(2):138-150. doi: 10.1159/000453588. Epub 2016 Dec 20.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022P000048
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Endoscopic Lung Volume Reduction in Patients With Advanced Emphysema Due to alpha1 Antitrypsin Deficiency
NCT01357460
TERMINATED
NA
Emphysematous Lung Sealant Therapy in Homogeneous Emphysema
NCT01728662
UNKNOWN
NA
Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction
NCT01041586
COMPLETED
PHASE1
Lung Volume Reduction Via Coils in Patients With COPD
NCT02246569
UNKNOWN
Safety and Efficacy of Endobronchial Valve for Bronchoscopic Lung Volume Reduction Surgery: a Prospective Pilot Study
NCT06349174
RECRUITING
NA
Lung Volume Reductions Surgery (LVRS) Study
NCT00018525
COMPLETED
NA
Comparison of the 1-min Sit-to-Stand Test to the 6-minute Walk Test in the Respiratory Functional Assessment of Pulmonary Fibrosis
NCT05449431
UNKNOWN
NA
Intermittent Intrapulmonary Deflation and Dyspnea Following Exercise in People With Chronic Obstructive Pulmonary Disease
NCT06956742
RECRUITING
NA
Ex-Vivo Lung Reconditioning
NCT02906436
COMPLETED
NA
Mechanisms of Vascular Damage in Patients With Chronic Obstructive Pulmonary Disease
NCT01020344
COMPLETED
NA
Improvement of Cardiovascular Function After Bronchoscopic Lung Volume Reduction Using Endobronchial Valves
NCT04556942
UNKNOWN
NA
A Registry Study of the AeriSeal® System or Lung Volume Reduction in Patients With Advanced Emphysema
NCT01449175
TERMINATED
The REDUCE EU Study - Endobronchial Thermal Liquid Ablation (ETLA) for the Treatment of Emphysema
NCT06655428
RECRUITING
NA
The Effect of Pulmonary Rehabilitation on Bronchoscopic Volume Reduction Process Success
NCT04347044
COMPLETED
NA
Targeted Intervention for Patient Centered Outcome in Patients With Idiopathic Pulmonary Fibrosis
NCT03480451
TERMINATED
NA
Post-Market Clinical Evaluation of the Zephyr Valve 5.5-LP EBV
NCT04161235
COMPLETED
Thorax Enlarging Surgery: a Novel Surgical Approach to Emphysema
NCT00650559
TERMINATED
NA
A Trial on the Effects of Bronchoscopic Lung Volume Reduction in Severe Emphysema.
NCT03474471
COMPLETED
NA
Evaluating the Effects of Surgical and Non-Surgical Treatment Options in People With Emphysema
NCT00675454
TERMINATED
Lung Volume Reduction Coil Treatment in Emphysema.
NCT01822795
UNKNOWN
PHASE3
AeriSeal System for Lung Volume Reduction
NCT01051258
COMPLETED
PHASE1/PHASE2
Evaluation of Physiologic Parameters to Study the Mechanism of Action of the Lung Volume Reduction Coil in Subjects With Homogeneous Emphysema
NCT01421082
COMPLETED
PHASE2/PHASE3
A Pilot Study to Assess Treatment of Patients With Homogeneous Emphysema Using Sequential Segmental Bronchoscopic Thermal Vapor Ablation (NEXT STEP)
NCT03670121
COMPLETED
NA
Feasibility Study of PneumRx's Lung Volume Reduction Coil (LVRC)
NCT01328899
COMPLETED
PHASE1/PHASE2
Evaluation of the PneumRx Lung Volume Reduction Coil to Treat Emphysema
NCT01220908
COMPLETED
NA